Evidence map›Paper›PMID 38819991›Full record

ArticleCell reports2024

Human antibodies in Mexico and Brazil neutralizing tick-borne flaviviruses.

Tomás Cervantes Rincón, Tania Kapoor, Jennifer R Keeffe, Luca Simonelli, Hans-Heinrich Hoffmann, Marianna Agudelo, Andrea Jurado, Avery Peace, Yu E Lee, Anna Gazumyan and 20 more

Abstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Tomás Cervantes RincónInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Tania KapoorLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Jennifer R KeeffeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Luca SimonelliInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Hans-Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Marianna AgudeloLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Andrea JuradoLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Avery PeaceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Yu E LeeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Francesca GuidettiLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Jasmine CantergianiInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Benedetta CenaInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Filippo BianchiniInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Elia TamagniniInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Simone G MoroInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Pavel SvobodaVeterinary Research Institute, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic; Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic; Department of Pharmacology and Pharmacy, Faculty of Veterinary Medicine, University of Veterinary Sciences, Brno, Czech Republic.
Federico CostaInstitute of Collective Health, Federal University of Bahia, Salvador, BA 40025, Brazil; Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Ministry of Health, Salvador, BA 40296, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06511, USA.
Mitermayer G ReisGonçalo Moniz Institute, Oswaldo Cruz Foundation, Ministry of Health, Salvador, BA 40296, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06511, USA; Faculty of Medicine of Bahia, Federal University of Bahia, Salvador 40025, Brazil.
Albert I KoGonçalo Moniz Institute, Oswaldo Cruz Foundation, Ministry of Health, Salvador, BA 40296, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06511, USA.
Brian A FallonDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, NY 10027, USA.
Santiago Avila-RiosNational Institute of Respiratory Diseases, Mexico City, CP 14080, Mexico.
Gustavo Reyes-TéranNational Institute of Respiratory Diseases, Mexico City, CP 14080, Mexico; Coordination of the National Institutes of Health and High Specialty Hospitals, Ministry of Health, Mexico City, CP 14610, Mexico.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Daniel RuzekVeterinary Research Institute, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic; Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
Luca VaraniInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Margaret R MacDonaldLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA. Electronic address: macdonm@rockefeller.edu.
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Electronic address: drobbiani@irb.usi.ch.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2014 to 2023
$26.0M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
Virology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2018 to 2022
$8.4M
Immunological drivers of the transition from epidemicity to endemicity of SARS-CoV-2 in a high transmission LMIC settingR01AI174105 · NIAID · YALE UNIVERSITY · PI Federico Costa, Derek A Cummings · 2023 to 2026
$3.0M
Natural History of Urban LeptospirosisR01AI052473 · NIAID · YALE UNIVERSITY · PI KO, ALBERT ICKSANG · 2003 to 2013
$2.8M
Ecoepidemiology of leptospirosis in the urban slums of BrazilR01TW009504 · FIC · YALE UNIVERSITY · PI BEGON, MICHAEL, CHILDS, JAMES EMORY · 2012 to 2016
$2.2M
Discovery and characterization of human neutralizing antibodies against Powassan virus in patients with Lyme disease for therapy, vaccine, clinical comorbidity profiling, and diagnostic purposes.R21AI142010 · NIAID · ROCKEFELLER UNIVERSITY · PI MACDONALD, MARGARET R · 2019 to 2020
$479k
FIC NIH HHS R01 TW009504NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR001866NIAID NIH HHS P01 AI138938NIAID NIH HHS R01 AI052473NIAID NIH HHS R01 AI174105NIAID NIH HHS R21 AI142010NIAID NIH HHS U01 AI151698NIAID NIH HHS U19 AI111825
6 · The paper itself

Abstract

Flaviviruses such as dengue virus (DENV), Zika virus (ZIKV), and yellow fever virus (YFV) are spread by mosquitoes and cause human disease and mortality in tropical areas. In contrast, Powassan virus (POWV), which causes severe neurologic illness, is a flavivirus transmitted by ticks in temperate regions of the Northern hemisphere. We find serologic neutralizing activity against POWV in individuals living in Mexico and Brazil. Monoclonal antibodies P002 and P003, which were derived from a resident of Mexico (where POWV is not reported), neutralize POWV lineage I by recognizing an epitope on the virus envelope domain III (EDIII) that is shared with a broad range of tick- and mosquito-borne flaviviruses. Our findings raise the possibility that POWV, or a flavivirus closely related to it, infects humans in the tropics.

Indexed as

Antibodies, NeutralizingAnimalsAntibodies, MonoclonalAntibodies, ViralBrazilEncephalitis Viruses, Tick-BorneEpitopesFemaleFlavivirusHumansMaleMexicoTicksAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesantibodiesCP: Immunologyflavivirusestick diseases

Identifiers

PMID38819991
PMCPMC11832053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.